CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • GRCL Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 6-K Filing

Gracell Biotechnologies (GRCL) 6-KGracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

Filed: 11 May 21, 4:05pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer
    GRCL similar filings
    • 4 Jun 21 Notice of Annual General Meeting of Shareholders
    • 21 May 21 Current report (foreign)
    • 20 May 21 Gracell Biotechnologies Reports First Quarter 2021 Unaudited
    • 11 May 21 Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer
    • 12 Apr 21 Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
    • 6 Apr 21 The collaboration will help Gracell leverage Lonza’s worldwide integrated services and expertise in CAR-T cell therapy manufacturing
    • 15 Mar 21 Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020
    Filing view
    Share this filing

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2021

    Commission file number: 001-39838

     

     

    Gracell Biotechnologies Inc.

     

     

    Building 12, Block B, Phase II

    Biobay Industrial Park

    218 Sangtian St.

    Suzhou Industrial Park, 215123

    People’s Republic of China

    (Address of Principal Executive Offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F  ☒            Form 40-F  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

     

     

     


    EXHIBIT INDEX

     

    Exhibit No.

      

    Description

    99.1  Press Release


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Gracell Biotechnologies Inc.
    By: 

    /s/ Yili Kevin Xie

    Name: Yili Kevin Xie
    Title: Chief Financial Officer

    Date: May 11, 2021

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn